 |
GenMark Diagnostics Reports First Quarter 2012 Results
May 8, 2012
|
23.7 KB |
| |
Quarterly Reagent Revenue Grows 213%
Installed Base Grows to 189 Analyzers
Quarterly Gross Margin Reaches 22%
Annuity Per Analyzer $46,000
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (Nasda...
|
|
GenMark Diagnostics Schedules First Quarter 2012 Financial Results and Conference Call for May 8, 2012
Apr 27, 2012
|
9.9 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its first quarter 2012 earnings results after market close on
Tuesday, May 8, 2012. Management will hold a conference call to review
the Company's first quarter 2012 performance starting at 4:30 p....
|
|
GenMark and Advanced Liquid Logic Enter into Agreement to Develop an All-Electronic Fully Integrated Diagnostic Platform
Apr 5, 2012
|
12.3 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc., (NASDAQ: GNMK) and Advanced Liquid Logic,
Inc. (ALL) announced today that they have entered into a Heads of
Agreement defining the key terms of a collaboration to develop an
all-electronic, fully integrated in-vitro diagnostic platform bringing
...
|
|
GenMark Diagnostics Appoints Richard B. Slansky Chief Financial Officer
Apr 2, 2012
|
10.2 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced today that it has
named Richard B. Slansky as Chief Financial Officer, effective April 23,
2012.
Slansky joins GenMark with more than 25 years of experience as a Chief
Financial Officer at both public a...
|
|
GenMark Enters into License Agreement with PerkinElmer for Microfluidics Patent Portfolio
Mar 29, 2012
|
11.7 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK), announced today that it has
entered into a license agreement with PerkinElmer, granting GenMark a
non-exclusive license under PerkinElmer's microfluidics patent portfolio.
"Completing this agreement strengthens GenMark's...
|
|
GenMark Diagnostics Reports Final Fourth Quarter and Fiscal Year 2011 Results
Mar 15, 2012
|
28.6 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported additional
financial information for the fourth quarter ended December 31, 2011
that was unavailable at the time it released preliminary financial
results on March 8, 2012. The additional information includes the
C...
|
|
GenMark Diagnostics Reports Preliminary Fourth Quarter and Fiscal Year 2011 Results
Mar 8, 2012
|
14.1 KB |
| |
Q4 2011 Revenues Grow 148% over Q4 2010 to $2.0 million
Q4 Placements of 26 Increase Installed Base to 167
Q4 2011 Positive Gross Margin of 17% to 20%
Fiscal Year 2011 Revenues Grow 92% over 2010
2011 Annuity per Analyzer Inc...
|
|
GenMark Diagnostics Schedules Fourth Quarter and Full Year 2011 Financial Results and Conference Call for March 8, 2012
Feb 24, 2012
|
9.9 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its fourth quarter and full year 2011 earnings results after
market closes on Thursday, March 8, 2012. Management will hold a
conference call to review the Company's fourth quarter and full year
...
|
|
GenMark Diagnostics Appoints Dr. Jorge Garces Senior Vice President, Research and Development
Feb 16, 2012
|
11.4 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK) announced that, effective
February 13, 2012, Dr. Jorge Garces has joined GenMark as Senior Vice
President, Research and Development.
Dr. Garces joins the GenMark team with extensive diagnostics experience,
includ...
|
|
GenMark Submits Respiratory Viral Panel Test for FDA 510(k) Clearance
Dec 21, 2011
|
10.1 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc., (NASDAQ: GNMK) announced today that it has
submitted to the U.S. Food and Drug Administration (FDA), for 510(k)
clearance, a Respiratory Viral Panel for use on its eSensor® XT-8
system. The test is designed to identify multiple viruses from
...
|
|
GenMark Diagnostics Reports Third Quarter 2011 Results
Nov 10, 2011
|
34.5 KB |
| |
Revenues Grow 90% and Placements Increase by 22 to 141
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial
results for the third quarter ended September 30, 2011.
Revenues for the three months ended September 30, 2011 were $1.3...
|
|
GenMark Diagnostics Schedules Third Quarter 2011 Financial Results and Conference Call for November 10, 2011
Oct 28, 2011
|
9.2 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its third quarter 2011 earnings results before market open on
Thursday, November 10, 2011. Management will hold a conference call to
review the Company's third quarter 2011 performance starting at ...
|
|
GenMark Diagnostics Reports Second Quarter 2011 Results
Aug 5, 2011
|
46.7 KB |
| |
Reagent Revenues Grow 104% and Placements Increase by 17 to 119
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial
results for the second quarter ended June 30, 2011.
Revenues for the three months ended June 30, 2011 were $901...
|
|
GenMark Diagnostics Schedules Second Quarter 2011 Financial Results and Conference Call for August 5, 2011
Jul 26, 2011
|
9.7 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its second quarter 2011 earnings results before market open on
Friday, August 5, 2011. Management will hold a conference call to review
the Company's second quarter 2011 performance starting at 9:0...
|
|
GenMark Announces Pricing of Public Offering of Common Stock
Jun 17, 2011
|
11.3 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a molecular diagnostics
company focused on developing and commercializing proprietary eSensor
detection technology, announced today the pricing of a public offering
of 7,065,600 shares of its common stock at a price to the public of
...
|
|
GenMark Diagnostics Reports First Quarter 2011 Results
May 9, 2011
|
23.1 KB |
| |
Revenues Grow 91% and Placements Increase by 20 to 102
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (Nasdaq:GNMK) today reported financial
results for the first quarter ended March 31, 2011.
Revenues and net loss for the three months ended March 31, 2011 were...
|
|
GenMark Diagnostics Schedules First Quarter 2011 Financial Results and Conference Call for May 9, 2011
May 3, 2011
|
9.2 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to
release its first quarter 2011 earnings results following the close of
market on Monday, May 9, 2011. Management will hold a conference call to
review the company's first quarter 2011 performance starting ...
|
|
Sue Pierce Appointed Vice President, Product Development of GenMark Diagnostics
Apr 25, 2011
|
10.5 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK)
announced that it has appointed Ms. Sue Pierce as Vice President,
Product Development, effective April 18, 2011.
Ms. Pierce joins the company with extensive diagnostics experience
including over 11 years at Venta...
|
|
GenMark Diagnostics Appoints Hany Massarany President and Chief Executive Officer
Apr 6, 2011
|
10.0 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of
automated molecular diagnostic testing systems, today announced that the
Board of Directors has appointed Hany Massarany as President and Chief
Executive Officer and a member of the Board of Directors.
...
|
|
Paul Ross Appointed CFO of GenMark Diagnostics
Mar 17, 2011
|
10.3 KB |
| |
CARLSBAD, Calif.--(BUSINESS WIRE)--
GenMark Diagnostics, Inc. (NASDAQ: GNMK)
announced today that it has appointed Mr. Paul Ross as Chief Financial
Officer, effective April 4, 2011.
Mr. Ross joins the company from Teledata Technology Solutions, a global
provider of information technology ...
|
|
|
